<DOC>
	<DOCNO>NCT00530114</DOCNO>
	<brief_summary>The primary objective study follow : 1 . To demonstrate AMG 223 produce statistically significant reduction serum phosphorus compare placebo 3 week treatment period subject CKD receive dialysis 2 . To describe dose response AMG 223 3 . To evaluate safety tolerability AMG 223</brief_summary>
	<brief_title>Study Assess Fixed Dosing AMG 223 Subjects With Chronic Kidney Disease Hemodialysis With Hyperphosphatemia</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Maintenance hemodialysis 3 time week least 3 month prior screen Single pool Kt/V least 1.2 urea reduction ratio least 65 % Serum phosphorus level 3.5 6.5 mg/dL inclusive screen No change ( ) type dose noninvestigational phosphate binder ( ) least 1 month prior screen Serum albumin &gt; 3.0 mg/dL screen If applicable , increase serum phosphorus great equal 1.5 mg/dL , serum phophorous level &gt; 5.5 mg/dL less equal 10 mg/dl washout period If applicable , stable dos ( defined change dose least 1 month prior screen ) Vitamin D replacement , calcimimetic agent , bedtime calcium supplement Willingness avoid intentional change diet fast diet Previous intolerance lead discontinuation polymerbased phosphate binder therapy History noncompliance phosphate binder therapy opinion investigator Anticipating schedule live relateddonor kidney transplant , prior recipient kidney transplant Current use antiarrhythmic antiseizure medication Active ethanol drug dependence abuse , exclude tobacco use A screening serum calcium ( correct albumin ) &lt; 8.4 mg/dL History bowel obstruction , swallow disorder , severe gastrointestinal disorder , major gastrointestinal surgery , gastric/duodenal ulcer within 6 month prior screen Subject pregnant , breast feeding , child bear potential use adequate contraceptive precaution Subject currently enrol yet complete least 30 day since end investigational device drug trial ( ) Subject experience myocardial infarction major surgery ( exclude vascular access surgery ) within 3 month prior screen Clinical evidence current malignancy and/or receive systemic chemotherapy/radiotherapy exception localize basal cell squamous cell carcinoma skin cervical intraepithelial neoplasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>